Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | TULIP: trastuzumab duocarmazine improved PFS in pre-treated HER2+ breast cancer

Cristina Saura Manich, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, presents results from the TULIP study, a Phase III trial comparing trastuzumab duocarmazine to physicians choice treatment in patients with pre-treated HER2-positive, locally advanced or metastatic breast cancer. In this trial, treatment with trastuzumab duocarmazine significantly improved progression-free survival in comparison to physians choice. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.